Humacyte, Inc. announced the presentation of positive preclinical progress of its development of a potential treatment for type 1 diabetes at two scientific meetings. Humacyte's BioVascular Pancreas (BVP) product candidate, currently in preclinical testing, incorporates stem cell-derived islets that are delivered using Humacyte's acellular tissue engineered vessel (ATEV) technology. At a presentation at the Breakthrough T1D (formerly, JDRF) Beta Cell Consortium Meeting in New York City, scientists presented data in which stem cell-derived islets, manufactured at Humacyte, were observed to restore normal blood sugar in diabetic mice.

In the mice, the stem cell-derived islets survival and continued insulin production throughout the three-month duration of the study. Islets also developed capillaries to support survival of the insulin-producing cells. The BVP is designed to supply the necessary oxygen to transplanted islets and support their successful implantation into patients.

The BVP and ATEV are investigational products and have not been approved for sale by the FDA or any other regulatory agency.